Sustained-release dexamethasone palmitate: Pharmacokinetics and efficacy in patients with activated inflammatory osteoarthritis of the knee

Clinical Drug Investigation

Volumn 21, Issue 6, 2001, Pages 429-436

  Bias, Peter ^a,b   Labrenz, Regine ^a,b   Rose, Peter ^a,b  

^a TEVA PHARMACEUTICALS   (Israel)

^b PAREXEL INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; LIPOTALON;

ADULT; ANALGESIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; KNEE OSTEOARTHRITIS; MALE; OSTEOARTHRITIS; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE PREPARATION;

EID: 0034972870     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200121060-00006     Document Type: Article

References (3)

1. Mizushima Y. Lipid microspheres as novel drug carriers. Drug Exp Clin Res XI 1985; 9: 595-600
2. Wagner J, Nelson E. Per cent absorbed time plots derived from blood level and/or urinary excretion data. J Pharm Sci 1963; 52: 610-1
3. Derendorf H, Möllmann HW, Barth J. Pharmakokinetik von intraartikulär applizierten Glukokortikoiden. Akt Rheumatol 1990; 15: 145-53